Global Tuberculosis Report -- 2012.pdf

More documents

Recommendations

Info

MOZAMBIQUEPopulation 2011 24 millionHIGH TB BURDEN | HIGH HIV BURDENEstimates of TB burden a 2011NUMBER (thousands) RATE (per 100 000 population)Mortality (excludes HIV+TB) 11 (4.0–22) 47 (17–91)Prevalence (includes HIV+TB) 120 (56–200) 490 (235–837)Incidence (includes HIV+TB) 130 (91–180) 548 (380–747)Incidence (HIV+TB) 83 (58–110) 347 (241–473)Case detection, all forms (%) 34 (25–49)TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 19 537 (45) Relapse 1 427 (34)Smear-negative 18 159 (42) Treatment after failure 238 (6)Smear-unknown/not done 0 (0) Treatment after default 242 (6)Extrapulmonary 5 504 (13) Other 2 345 (55)Other 0 (0)Total new 43 200 Total retreatment 4 252Mortality (excludes HIV+TB) (rateper 100 000 population per year)Prevalence(rate per 100 000 population)2502001501005001990 1995 2000 2005 2010250020001500100050001990 1995 2000 2005 2010Other (history unknown) 0Total new and relapse 44 627 Total cases notifi ed 47 452New casesSMEAR-NEGATIVE/SMEAR-POSITIVE UNKNOWN/NOT DONE EXTRAPULMONARYM:F ratioAge < 15 324 2 180 710Incidence (rate per 100 000population per year)12001000800600400200Laboratories 2011Smear (per 100 000 population) 1.8Culture (per 5 million population) 0.4Drug susceptibility testing (per 5 million population) 0.4Is second-line drug susceptibility testing available?Yes, in and outside countryIs there a national reference laboratory?YesTreatment success rate 2010 (%)New smear-positiveIs rifampicin used throughout(and/or culture-positive) 85 treatment for new patients? YesNew smear-negative/extrapulmonaryRetreatmentTB/HIV 2011 NUMBER (%)TB patients with known HIV status 41 896 (88)HIV-positive TB patients 26 538 (63)HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 24 095 (91)HIV-positive TB patients on antiretroviral therapy (ART) 7 661 (29)HIV-positive people screened for TBHIV-positive people provided with IPT 17 064Estimates of MDR-TB burden 2011 a NEW RETREATMENT% of TB cases with MDR-TB 3.5 (2.2–4.8) 12 (0.0–25)MDR-TB cases among notifi edpulmonary TB cases 1 300 (830–1 800) 510 (0–1 100)Reported cases of MDR-TB 2011 NEW RETREATMENT TOTALCases tested for MDR-TB 206 (1%) 443 (10%) 663Laboratory-confi rmed MDR-TB cases 76 202 283Patients started on MDR-TB treatment 146Treatment success rate (%)Number of patients01990 1995 2000 2005 2011908070605040302010030 00020 00010 000040Incidence Incidence (HIV+TB) Notifications1996 1998 2000 2002 2004 2006 2008 2010New smear-positive (and/or culture-positive)New smear-negative/extrapulmonaryRetreatment2003 2004 2005 2006 2007 2008 2009 2010 2011HIV-positive TB patients on CPT on ARTFinancing TB control 2012 2013Total budget (US$ millions) 37 35Available funding (US$ millions) 8.5 8.1% of budget funded 23 23% available funding from domestic sources 29 24% available funding from the Global Fund 42 46US$ millions30201002006 2007 2008 2009 2010 2011 2012 2013aRanges represent uncertainty intervals.Total budgetAvailable fundingGLOBAL TUBERCULOSIS REPORT 2012 Data can be downloaded from www.who.int/tb/data 117
MYANMARPopulation 2011 48 millionHIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDENEstimates of TB burden a 2011NUMBER (thousands) RATE (per 100 000 population)Mortality (excludes HIV+TB) 23 (11–40) 48 (22–84)Prevalence (includes HIV+TB) 240 (190–310) 506 (390–637)Incidence (includes HIV+TB) 180 (160–210) 381 (326–439)Incidence (HIV+TB) 18 (15–22) 38 (31–45)Case detection, all forms (%) 74 (64–87)Mortality (excludes HIV+TB) (rateper 100 000 population per year)2001501005001990 1995 2000 2005 2010TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 42 324 (32) Relapse 4 606 (42)Smear-negative 62 038 (47) Treatment after failure 1 525 (14)Smear-unknown/not done Treatment after default 542 (5)Extrapulmonary 27 769 (21) Other 4 336 (39)OtherTotal new 132 131 Total retreatment 11 009Prevalence(rate per 100 000 population)1500100050001990 1995 2000 2005 2010Other (history unknown)Total new and relapse 136 737 Total cases notifi ed 143 140New casesM:F ratio 1.9Age < 15 307SMEAR-NEGATIVE/SMEAR-POSITIVE UNKNOWN/NOT DONE EXTRAPULMONARYLaboratories 2011Smear (per 100 000 population) 0.9Culture (per 5 million population) 0.2Drug susceptibility testing (per 5 million population) 0.2Is second-line drug susceptibility testing available?Is there a national reference laboratory?Treatment success rate 2010 (%)Yes, outside countryNew smear-positiveIs rifampicin used throughout(and/or culture-positive) 86 treatment for new patients? YesNew smear-negative/extrapulmonary 89Retreatment 73YesIncidence (rate per 100 000population per year)Treatment success rate (%)50040030020010001990 1995 2000 2005 2011Incidence Incidence (HIV+TB) Notifications1008060402001996 1998 2000 2002 2004 2006 2008 2010TB/HIV 2011 NUMBER (%)TB patients with known HIV status 4 496 (3)HIV-positive TB patients 900 (20)HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 900 (100)HIV-positive TB patients on antiretroviral therapy (ART) 724 (80)HIV-positive people screened for TB 12 120HIV-positive people provided with IPT 361Estimates of MDR-TB burden 2011 a NEW RETREATMENT% of TB cases with MDR-TB 4.2 (3.1–5.6) 10 (6.9–14)MDR-TB cases among notifi edpulmonary TB cases 4 400 (3 200–5 800) 1 100 (760–1 500)Number of patients6000500040003000200010000New smear-positive (and/or culture-positive) RetreatmentNew smear-negative/extrapulmonary2003 2004 2005 2006 2007 2008 2009 2010 2011Reported cases of MDR-TB 2011 NEW RETREATMENT TOTALHIV-positive TB patients on CPT on ARTCases tested for MDR-TBLaboratory-confi rmed MDR-TB cases 690Patients started on MDR-TB treatment 163Financing TB control 2012 2013Total budget (US$ millions) 29 31Available funding (US$ millions) 10 9.3% of budget funded 34 30% available funding from domestic sources 7% available funding from the Global Fund 79 89US$ millions353025201510502006 2007 2008 2009 2010 2011 2012 2013aRanges represent uncertainty intervals.Total budgetAvailable funding118 Data can be downloaded from www.who.int/tb/data GLOBAL TUBERCULOSIS REPORT 2012
Page 2 and 3:
GLOBALTUBERCULOSISREPORT2012
Page 4 and 5:
ContentsAbbreviationsivAcknowledgem
Page 6 and 7:
AcknowledgementsThis report on glob
Page 8 and 9:
WHO Western Pacific RegionShalala A
Page 10 and 11:
Executive SummaryThe World Health O
Page 12 and 13:
CHAPTER 1IntroductionBOX 1.1Basic f
Page 14 and 15:
TABLE 1.1 Targets for the scale-up
Page 16 and 17:
TABLE 1.2 Reporting of data in the
Page 18 and 19:
BOX 2.1Uncertainty in estimates of
Page 20 and 21:
TABLE 2.2 Estimated burden of disea
Page 22 and 23:
FIGURE 2.5 Estimated TB incidence r
Page 24 and 25:
FIGURE B2.2.1Reporting of notificat
Page 26 and 27:
FIGURE 2.8Estimated TB incidence ra
Page 28 and 29:
FIGURE 2.11 Countries (in blue) for
Page 30 and 31:
FIGURE 2.12 Trends in estimated TB
Page 32 and 33:
● producing and widely disseminat
Page 34 and 35:
FIGURE 2.16 Progress in global cove
Page 36 and 37:
BOX 2.6Efforts by the Task Force to
Page 38 and 39:
CHAPTER 3TB case notificationsand t
Page 40 and 41:
BOX 3.1 1Definitions of TB casesDef
Page 42 and 43:
TABLE 3.3 Contribution of public-pr
Page 44 and 45:
BOX 3.4Integrating community-based
Page 46 and 47:
TABLE 3.4 Estimates of the case det
Page 48 and 49:
TABLE 3.5 Treatment success for new
Page 50 and 51:
CHAPTER 4Drug-resistant TBKEY FACTS
Page 52 and 53:
FIGURE 4.2 Percentage of new TB cas
Page 54 and 55:
BOX 4.1Frequencies of resistance to
Page 56 and 57:
FIGURE 4.6 Number of MDR-TB cases e
Page 58 and 59:
FIGURE 4.7Notified cases of MDR-TB
Page 60 and 61:
egimens globally, providing more su
Page 62 and 63:
5.1 Funding for TB care and control
Page 64 and 65:
TABLE 5.2 NTP budgets, available fu
Page 66 and 67:
FIGURE 5.5Trends in domestic and do
Page 68 and 69:
FIGURE 5.6Domestic funding as a per
Page 70 and 71:
FIGURE 5.8Cost per TB patient succe
Page 72 and 73:
FIGURE 5.10 Total cost and unit cos
Page 74 and 75:
● The 14 countries not included i
Page 76 and 77: on public health by an external Exp
Page 78 and 79: evised as a result of the introduct
Page 80 and 81: TABLE 6.2 Incorporation of WHO poli
Page 82 and 83: FIGURE 6.3The Supranational Referen
Page 84 and 85: of TB disease by 65%, irrespective
Page 86 and 87: FIGURE 7.3Percentage of TB patients
Page 88 and 89: BOX 7.1Accelerating progress in pro
Page 90 and 91: TABLE 7.2 Assumptions used to estim
Page 92 and 93: FIGURE 8.1 The development pipeline
Page 94 and 95: sputum specimens and TB isolates fr
Page 96 and 97: cal trial sites and building labora
Page 98: new TB vaccine candidate. A Phase I
Page 102 and 103: This annex explains the methods tha
Page 104 and 105: 2011. On average, 15 data points we
Page 106 and 107: may suffer from biases. These biase
Page 108 and 109: TABLE A1.3Parameter estimates used
Page 110 and 111: 5. Estimates of TB prevalence, 1990
Page 112: the Republic of Moldova, Romania, t
Page 116 and 117: AFGHANISTANPopulation 2011 32 milli
Page 118 and 119: BRAZILPopulation 2011 197 millionHI
Page 120 and 121: CHINAPopulation 2011 1 348 millionH
Page 122 and 123: ETHIOPIAPopulation 2011 85 millionH
Page 124 and 125: INDONESIAPopulation 2011 242 millio
Page 128 and 129: NIGERIAPopulation 2011 162 millionH
Page 130 and 131: PHILIPPINESPopulation 2011 95 milli
Page 132 and 133: SOUTH AFRICAPopulation 2011 50 mill
Page 134 and 135: UGANDAPopulation 2011 35 millionHIG
Page 136 and 137: VIET NAMPopulation 2011 89 millionH
Page 138: ANNEX 3Regional profiles
Page 141 and 142: WHO REGION OF THE AMERICASPopulatio
Page 143 and 144: WHO EUROPEAN REGIONPopulation 2011
Page 145 and 146: WHO WESTERN PACIFIC REGIONPopulatio
Page 148 and 149: SUMMARY BY WHO REGIONTable A4.1 Est
Page 150 and 151: MORTALITY (EXCLUDING HIV) PREVALENC
Page 152 and 153: NEW AND RELAPSENOTIFICATION RATE aY
Page 154 and 155: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 156 and 157: AFRICAN REGIONTable A4.1 Estimates
Page 162 and 163: INCIDENCE (INCLUDING HIV) INCIDENCE
Page 164 and 165: NEW AND RELAPSENOTIFICATION RATE aY
Page 166 and 167: NEW AND RELAPSENOTIFICATION RATE a1
Page 168 and 169: TREATMENT SUCCESS (%) a1995-2010YEA
Page 174 and 175: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 176 and 177:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
Page 178 and 179:
MALEYEAR 0-14 15-24 25-34 35-44 45-
Page 180 and 181:
REGION OF THE AMERICASTable A4.1 Es
Page 182 and 183:
MORTALITY (EXCLUDING HIV) PREVALENC
Page 184 and 185:
Page 186 and 187:
INCIDENCE (INCLUDING HIV) INCIDENCE
Page 188 and 189:
NEW AND RELAPSENOTIFICATION RATE a1
Page 190 and 191:
Page 192 and 193:
% OF COHORTTREATMENT SUCCESS (%) a1
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
-% OF TB PATIENTS WITHKNOWN HIV STA
Page 200 and 201:
Page 202 and 203:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
Page 204 and 205:
EASTERN MEDITERRANEAN REGIONTable A
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
EUROPEAN REGIONTable A4.1 Estimates
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
SOUTH-EAST ASIA REGIONTable A4.1 Es
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258:
SMEAR LABS % OF SMEARPER 100K LABS
Page 261 and 262:
Estimates of mortality, prevalence
Page 263 and 264:
YEARPOPULATION(MILLIONS)MORTALITY (
Page 265 and 266:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 267 and 268:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 269 and 270:
Page 271 and 272:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 273 and 274:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
SMEAR LABS % OF SMEARPER 100K LABS
show all

Global Tuberculosis Report -- 2012.pdf

Create successful ePaper yourself

Delete template?

Save as template?